Clobazam interactions
Full monograph for ClobazamCheck it against another medicine
Medicines
344 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Clozapine | Major | Synergy | Benzodiazepines and clozapine may have additive effects on respiratory and cardiovascular function. Ataxia, excessive salivation, hypotension, collapse… | 14 sources — open the full entry |
| Fentanyl Citrate | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Morphine Sulfate | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Nalbuphine Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Oxymorphone Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Paracetamol + Tramadol Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Pentazocine | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Pethidine Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Remifentanil Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Tapentadol Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Tramadol Hydrochloride | Major | Synergy | Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics… | 1 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Acetazolamide | Moderate | Antagonism | Benzodiazepines may counteract the beneficial effects of acetazolamide in preventing altitude sickness by inhibiting respiratory responses to hypoxia. | 8 sources — open the full entry |
| Adalimumab | Moderate | Metabolism | Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF)… | 19 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Alprazolam | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration of clobazam with inhibitors of CYP450 2C19 may significantly increase the plasma concentrations of its active metabolite, N-desmethylclobazam… | 7 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Metabolism | Coadministration with clobazam may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. The mechanism is decreased… | 6 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Metabolism · Synergy | Coadministration with clobazam may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. The mechanism is decreased…2 documented mechanisms | 50 sources — open the full entry |
| Amlodipine Besilate | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 7 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 7 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 7 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4… | 4 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these… | 5 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration of clobazam with inhibitors of CYP450 2C19 may significantly increase the plasma concentrations of its active metabolite, N-desmethylclobazam… | 7 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartrate | Moderate | Synergy | The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.2 documented mechanisms | 10 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Atenolol | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 11 sources — open the full entry |
| Atomoxetine Hydrochloride | Moderate | Metabolism | Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of atomoxetine, which is primarily metabolized by the… | 3 sources — open the full entry |
| Atracurium Besilate | Moderate | Others | Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported. | 9 sources — open the full entry |
| Azilsartan Medoxomil | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…3 documented mechanisms | 18 sources — open the full entry |
| Baclofen | Moderate | Synergy | Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these… | 44 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism · Synergy | The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.2 documented mechanisms | 14 sources — open the full entry |
| Benzocaine + Butamben + Tetracaine Hydrochloride | Moderate | Synergy | The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants. | 7 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Synergy | The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants. | 7 sources — open the full entry |
| Betaxolol Hydrochloride | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Bisoprolol Fumarate | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 18 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)…2 documented mechanisms | 11 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Synergy | Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants)… | 11 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
4 sources
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
- "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):
Conditions
Conditions in which Clobazam needs care, as documented in this source.
Alcoholic Intoxication
MajorThe use of benzodiazepines with alcohol is not recommended. Patients with acute alcohol intoxication exhibit depressed vital signs. The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur. Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.
14 sources
- "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn (2002):
- "Product Information. Valium (diazepam)." Roche Laboratories (2002):
- "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories (2002):
- "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation (2001):
- "Product Information. Halcion (triazolam)." Pharmacia and Upjohn (2001):
- "Product Information. Dalmane (flurazepam)." Roche Laboratories (2001):
- "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical (2001):
Show all 14 sourcesShow fewer sources
- "Product Information. Klonopin (clonazepam)." Roche Laboratories (2001):
- "Product Information. Prosom (estazolam)." Abbott Pharmaceutical (2022):
- "Product Information. Librium (chlordiazepoxide)." Roche Laboratories (2001):
- "Product Information. Doral (quazepam)." Wallace Laboratories (2001):
- "Product Information. Versed (midazolam)." Roche Laboratories (2001):
- "Product Information. Onfi (clobazam)." Lundbeck Inc (2011):
Substance-Related Disorders
MajorBenzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.
14 sources
- "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn (2002):
- "Product Information. Valium (diazepam)." Roche Laboratories (2002):
- "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories (2002):
- "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation (2001):
- "Product Information. Halcion (triazolam)." Pharmacia and Upjohn (2001):
- "Product Information. Dalmane (flurazepam)." Roche Laboratories (2001):
- "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical (2001):
Show all 14 sourcesShow fewer sources
- "Product Information. Klonopin (clonazepam)." Roche Laboratories (2001):
- "Product Information. Prosom (estazolam)." Abbott Pharmaceutical (2022):
- "Product Information. Librium (chlordiazepoxide)." Roche Laboratories (2001):
- "Product Information. Doral (quazepam)." Wallace Laboratories (2001):
- "Product Information. Onfi (clobazam)." Lundbeck Inc (2011):
- "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc (2020):
Depressive Disorder
ModerateBenzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation. Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents. Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.
13 sources
- "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn (2002):
- "Product Information. Valium (diazepam)." Roche Laboratories (2002):
- "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories (2002):
- "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories (2001):
- "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation (2001):
- "Product Information. Halcion (triazolam)." Pharmacia and Upjohn (2001):
- "Product Information. Dalmane (flurazepam)." Roche Laboratories (2001):
- "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical (2001):
Show all 13 sourcesShow fewer sources
- "Product Information. Klonopin (clonazepam)." Roche Laboratories (2001):
- "Product Information. Prosom (estazolam)." Abbott Pharmaceutical (2022):
- "Product Information. Librium (chlordiazepoxide)." Roche Laboratories (2001):
- "Product Information. Doral (quazepam)." Wallace Laboratories (2001):
- "Product Information. Onfi (clobazam)." Lundbeck Inc (2011):
Therapeutic duplication
Drug classes that overlap with Clobazam, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
benzodiazepines
The recommended maximum number of medicines in the 'benzodiazepines' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'benzodiazepines' category.
Example product in the source data (US market): Librax
benzodiazepines
The recommended maximum number of medicines in the 'benzodiazepines' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'benzodiazepines' category.
Example product in the source data (US market): Limbitrol ds
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Phrenilin with caffeine and codeine
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Phrenilin
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Butabarbital/hyoscyamine/phenazopyridine
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Aspirin/butalbital/caffeine/codeine
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Micrainin
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Nodolor
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Laniroif
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Phenohytro
tranquilizers
The recommended maximum number of medicines in the 'tranquilizers' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'tranquilizers' category.
Example product in the source data (US market): Nonbac